Sarin J, DeRossi S S, Akintoye S O
Department of Oral Medicine, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Oral Dis. 2008 Apr;14(3):277-85. doi: 10.1111/j.1601-0825.2007.01381.x.
Osteonecrosis of the jaws is a major complication associated with long-term use of bisphosphonates. While osteonecrosis can arise from other precipitating conditions, bisphosphonate-induced jaw osteonecrosis (BJON) is highly associated with long-term administration of pamidronate (Aredia) and zoledronic acid (Zometa), which are two intravenous bisphosphonate formulations. The underlying pathogenesis of BJON and its site-specific presentation still remain to be fully elucidated. This review will discuss clinically available bisphosphonates, current opinions, pathogenesis, and management guidelines for bisphosphonate-induced jaw osteonecrosis.
颌骨骨坏死是长期使用双膦酸盐类药物相关的一种主要并发症。虽然骨坏死可由其他诱发情况引起,但双膦酸盐类药物所致颌骨骨坏死(BJON)与长期使用帕米膦酸二钠(阿可达)和唑来膦酸(择泰)密切相关,这两种药物均为静脉用双膦酸盐制剂。BJON的潜在发病机制及其部位特异性表现仍有待充分阐明。本综述将讨论临床上可用的双膦酸盐类药物、当前观点、发病机制以及双膦酸盐类药物所致颌骨骨坏死的管理指南。